To determine whether the menin-MLL interaction is essential in KAT6A-rearranged leukemia, we evaluated the therapeutic potential of Revumenib, a clinical-stage menin-MLL inhibitor effective in MLL-rearranged AML [40]. Here, KAT6A is linked to leukemia.